Fortress Biotech, Inc.
FBIO
$2.72
$0.010.37%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 17.49% | 12.74% | 8.05% | -5.13% | -10.21% |
| Total Other Revenue | -32.82% | 114.00% | 102.30% | -84.16% | -87.52% |
| Total Revenue | 15.46% | 14.50% | 9.69% | -23.56% | -28.23% |
| Cost of Revenue | -50.84% | -44.56% | -57.79% | -46.68% | -45.49% |
| Gross Profit | 387.39% | 1,564.40% | 251.40% | 886.00% | 192.33% |
| SG&A Expenses | -39.22% | -8.97% | 10.21% | 41.02% | 47.45% |
| Depreciation & Amortization | 7.65% | 17.56% | 24.39% | -32.78% | -27.27% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.99% | -18.75% | -18.64% | -7.42% | -6.63% |
| Operating Income | 71.70% | 39.56% | 33.96% | -8.76% | -12.77% |
| Income Before Tax | 263.98% | 225.59% | 72.02% | 56.55% | 16.90% |
| Income Tax Expenses | 1,051.11% | 972.10% | -295.06% | -19.20% | -22.12% |
| Earnings from Continuing Operations | 258.02% | 221.04% | 72.77% | 56.42% | 16.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -139.37% | -101.78% | -46.93% | -22.92% | 11.60% |
| Net Income | 859.12% | 410.40% | 114.82% | 108.22% | 63.80% |
| EBIT | 71.70% | 39.56% | 33.96% | -8.76% | -12.77% |
| EBITDA | 75.06% | 41.83% | 35.64% | -9.15% | -13.86% |
| EPS Basic | 394.00% | 264.85% | 98.17% | 93.86% | 70.25% |
| Normalized Basic EPS | 1,174.01% | 1,459.27% | 160.14% | -50.12% | 148.38% |
| EPS Diluted | 327.05% | 235.41% | 95.71% | 91.86% | 69.02% |
| Normalized Diluted EPS | 1,002.05% | 1,177.37% | 105.16% | -56.90% | 145.52% |
| Average Basic Shares Outstanding | 22.13% | 28.26% | 36.68% | 61.70% | 84.37% |
| Average Diluted Shares Outstanding | 31.09% | 45.58% | 47.52% | 75.05% | 89.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | 1.00% | 1.00% |